Index

Abbott (pharmaceutical company), 238, 244
Abraham, John, 22–3
absence of evidence, as evidence of absence, 93
academic research organizations, 209 see also clinical development service providers
access-to-medicine programs, 253
accountability, liability model of, 214
accumulation of pharmaceuticals, logic of, 33–4
ACE (angiotensin-converting-enzyme) inhibitors 90–93, 101
lack of effectiveness in black populations, 91 see also Vasodilator in Heart Failure Trials (V-Heft); Cohn, Jay
Achieving Clarity, Renewing Confidence (publication plan), 152 see also Wyeth; publication planning and planners
acopeadores (barbacoa buyers), 188
active-control trial, 213
actor-network theory (ANT), 166, 175
Adams, Samuel Hopkins, 3
Adams, Vincanne, 175
Addo, S., 152 see also authors; PC(2)
Adis Communications, 154
advertisements, as clinical trial recruitment, 198–200
Aetna (health insurance), coverage policy, 83
African American heart failure patients, 50, 94
African American Heart Failure Trial (A-Heft), 91, 95
as articulation of problems and solutions, 91
Association of Black Cardiologists’ (ABC) role in, 92
agency, conflated with consumer identity, 144
Ahari, Shahram, 9
AIDS drugs see HIV/AIDS drugs
Aldomet (alpha-methyl-dopa, catecholamine blocker), 64
ALTACE (ACE-Inhibitor), 101
alternative medicine advocates of, 33
global status of, 169
hierarchies within, 169
Althusser, Louis, 35, 39
Alzheimer’s disease, 25–6, 201–2, 206
American College of Obstetricians and Gynecologists, 79
American Medical Association (AMA), 53, 59, 128–9
Council on Drugs, 57
House of Delegates, 111
American Pharmaceutical Manufacturers’ Association (APMA), 57–8
American Psychiatric Association (APA), 76, 81
Committee on Women, 76
debate over PMDD, 78
Index

Division of Research, 78
PMDD Work Group, 84
amlodipine (Norvasc, calcium antagonist), 153

Androgen Deficiency in Women: Definition, Diagnosis, and Classification
(conference), 108 see also University of Medicine and Dentistry of New Jersey; Robert Wood Johnson Medical School
androgen deficiency syndrome in women, development of consensus statement on, 108

Angell, Marcia, 22, 219
Annals of the New York Academy of Sciences, 57
anti-Novartis alliance, 252, 254–5
antidepressant drugs, 28, 70, 73, 78, 143
antihypertensive drugs, 62
  effects of Diuril, 54
  modern era of, 52
antiretroviral drugs (ARVs), 8, 236–8, 240, 246, 250
copying, 237–44
ANVISA (Brazilian drug regulatory body), 210, 239, 241
Appadurai, Arjun, 4
Applbaum, Kalman, 9, 122
Applezweig, Norman, 184
Arlotto, Michael, 227 see also Quintiles
Aronowitz, Robert, 89
Association for Clinical Research Organizations (ACRO), 219
Association of Black Cardiologists (ABC), 87, 91–2, 96, 98–101
hq (Atlanta), 100
funding to participate in evidence-based medicine, 92
role in African American Heart Failure Trial (A-Heft), 92 see also African American Heart Failure Trial (A-Heft)
Association of Korean Oriental Medicine (AKOM), 169
AstraZeneca (pharmaceutical company), 137
attention deficit disorder (ADD), 109
study of, 204 see also Ritalin
atypical antipsychotics, lawsuits against manufacturers, 137 see also Bristol-Myers Squibb; Pfizer; Janssen; AstraZeneca; Eli Lilly
Australasian Journal of Bone and Joint Medicine (AJBJM), The, 162
authors (on pharmaceutical company manuscripts), 151–2, 158, 161
access to study data, 160

and ghost management of research and publication, 158
as visible authorities, 150, 158
deadbeat, 158
authorship, 158
  and industry control, 161
International Committee of Medical Journal Editors (ICMJE) criteria for, 158
Avicenna, 2
awareness, facilitated, 37
Ayurvedic doctors, 171
AZT Trial, 212–14

Bae (Professor of Korean medicine), 168, 173, 176 see also Korean medicine (KM)
barbasco flour, 190
barbasco yam, 180–183, 185–91
diosgenin yields, 186 see also dioscorea roots
  as steroid hormone substitute, 184
barbasqueros (harvesters of barbasco), 187, 191
Barr, Michael and Rose, Diana, 28
barrios populares, 262
Basheer, Shamnad, 251–2
Basu, Soumita, 251
Batista (President Fulgencio of Cuba), presidential decree, 186
Baudrillard, Jean, 72, 83
Bauer, Martin, 112–13
beneficios for processing barbasco, 188–9
Berman, Jennifer and Laura, 113, 114 see also researchers, as media celebrities
Berne Declaration, 250
Besselaar, Hein, 211
Beyer, Karl, 54–5, 62
Bhatt, Arun, 228
BiDil (hydralazine and isosorbide dinitrate), 6, 50, 87, 100
commercial failure of, 94, 99
in the context of heart failure, 89, 90
effectiveness in A-Heft, 91
in framework of pharmacogenomics, 93 see also Fullwiley, Duana
hearing on approval, 92 see also Food and Drug Administration (FDA), hearing on BiDil’s approval
as methods patent, 90–91
as pharmakon, 95
undecidabilities of, 87, 99 see also Derrida, Jacques
Biehl, Joao, 217–18
biocapital
  globalizing dynamics of, 222–3
structural logics of, 231
study of, 223, 229, 232
bioequivalence, 263
biographical approach, 4 see also, Kopytoff, Igor
biography of a drug, 5
biological determinism, 192
biomedical economy, 223
biomedical enhancement, 26
biotechnology revolution, 28
Black Power, 96
black-box, of the pharmaceutical, 264
Bliss, Michael, 3
blockbuster drugs, 77, 87, 133, 143, 210
lack of potential for BiDil as, 90
Bombay Stock Exchange, 229
Borja, Alejandro Villar, 193
Boston Globe (newspaper), 72
Bouchard, P., 152 see also authors; PC(2)
boundary, sociobiological of race, 98
boundary work
by BiDil’s critics, 98
drugs as objects for, 98
between PMD and PMS, 82
to separate remedy and harm of BiDil, 95
Brand, Ron, 129 see also IMS Consulting
branded identity, 71, 82–3
Brazil, 210, 236
government, 239
Health Ministry, 238
pharmaceutical industry in, 239, 242
private laboratories in, 239–41
public laboratories in, 237, 239–41, 243, 246
state as health entrepreneur, 239
breast cancer, 25
Brest, Albert, 52
Brigham and Women’s Hospital, 3
Bristol-Myers Squibb (pharmaceutical company), 137
British Commission on Intellectual Property Rights, 246
Bureau of Applied Social Research (Columbia University), 3
Busfield, Joan, 21
cabeza de negro, 184–6, 191 see also dioscorea roots
campesinos, Mexican, 181, 183, 186–7, 189, 192
Cancer Patients Aid Association (CPAA), 250–252, 254–7
capacity building, 223, 226
capitalism, 168, 175, 258
transformation of, 247
Caplan, Paula, 76, 78
Cárdenas government of Mexico, 184, 192
Carus Clinical Communications (publication planning firm), 156
Cassier, Maurice, 10–11, 236
catecholamine blockers, 64
Centers for Disease Control (CDC), 213
CenterWatch, 219
Centre for Alternative Medicine (Harvard Medical School), 169
channel captain, 135, 142–3 see also channel marketing
channel marketing, 133, 141–2
coordination, 135
motivational logic of, 145
power, 134, 142
primary care providers (PCPs) as site of, 138
share of voice (SOV) leadership, 140 see also marketing, strategies
Chaudhuri, Sudip, 257
checklists, diagnosis through, 40, 42, 43
chemical imbalances, language of in Sarafem campaigning, 80
Chemical Pharmaceutical Generic Association, 224
Chennai Assistant Controller of Patents and Design, 250
Chennai High Court, 250, 252, 254
Chennai Patent Office, 249
Chilpa, Ricardo Ryes, 192
chlorothiazide (Diuril), 59, 63 see also Diuril
Choi (Doctor of Korean Medicine), 173 see also Korean medicine (KM); hybridization, of medical practices
cholera, 5
Chronic Myeloid Leukemia (CML), 248
Ciba (pharmaceutical company), 62, 64, 183
CIMS (Current Index of Medical Specialities), 257
Cipla (Pharmaceutical company), 250
circulation, of pharmaceutical knowledge, 122
citizenship, 247, 262
corporate, 247
and procorporate citizens, 254–5
CITU (Centre of Indian Trade Unions), 251
Clarityne (loratidine, antihistamine), 262
classification of doctors, as a marketing strategy, 123–9
Cleveland Clinic, 62
climate of believability about a new drug, 62
clinical depression, signs of, 34
clinical development service providers, 208–9 see also clinical trials
clinical research, geography of, 56
clinical trials, 152, 157
adverse events, 9, 216, 230–231
and attractiveness index, 226
and biocapital, 222–3, 228–9, 231
design of, 36
designers of, 198
dynamics of in India, 223, 229
for female sex hormone therapy, 192
globalization of, 208–10, 216, 231
as gold standard, 8
information about, 200
linkages with commodification techniques, 108
in nontraditional research areas, 208
operational model, 210
and paradigm of expected failure, 218
participation and configuration of subjects in India, 230
participation and demographic trends, 201
participation and disadvantaged populations, 212, 214–15
participation and inclusion criteria, 215
participation and income as motivation, 203
participation and lack of legal recourse for harms incurred by, 218
participation and progressive diseases as motivation, 201–2
participation and recruitment, 8, 195, 197–8, 205, 208, 215, 224, 232
participation and treatment naïveté, 212
participation, health insurance status as motivation, 202–3
Phase I research, 201, 205, 222, 229, 232
Phase II research, 201, 223
Phase II research, of testosterone-replacement patch for women, 108
Phase III research, 201, 209, 219, 223, 230
phases of, 211, 222, 223
in the private sector, 196, 210, 218, 223
reevaluation of structural conditions of, 205
as regulation, 222, 227
reporting, 159
as social institutions, 209
socio-economic harms, 216
sponsorship by pharmaceutical companies, 151, 161
transformation of, 180, 214
uncertainty of, 218
volunteer retention in India, 229
code of medical ethics, 114 see also medical exceptionalism, golden age of
Cofield, Juan, 88, 97–9
cognitive enhancement drugs, 26
Cohn, Jay, 90–91, 93, 100
Coleman, James S., 3
collaborative competitorship, 143
collaborative model of informed consent, 197–8
see also informed consent, alternative models of
colonized futures, 30
Columbus, Christopher, 7
Comaroff, Jean, 4
commercialization of science, 196
commodification techniques, 107
contributions by researchers, 108
female sexual dysfunction (FSD) research as, 114
links with clinical trial research, 108
links with exchange networks and technoscientific development, 106
organization of continuing medical education (CME) conferences as, 112
commoditization, as enemy of marketing, 139
see also patents, value of
communication objective, 38
Communist Party of India [Marxist], 251
compliance
monitoring, 36–7
branded, 36, 44
information for, 37
compulsory licensing, 236, 238, 243–5
compulsory purchase (eminent domain), 145
Congressional Black Caucus, 92, 96
Conrad, Peter, 21–2, 26
consensus conferences, 108–9
Constitutional, Judicial and Citizenship Commission, Brazil, 237, 244
construction of disease, by corporations, 21
consumer advocacy, overlap with patient advocacy, 73
consumer markets, creation of, 26, 108
consumer movements, 115
commercialization of, 113
consumerism, language of, 115
BiDil’s failure to fit, 94
paradigm for health-care utilization, 134
consumers
junctions with technological procedures, 106
processes through which individuals are transformed, 109
consumers-have-the-power model, 144–5
consumers of healthcare, as codependent choicemakers, 134
Consumers Union, 6
consumption junction, 111 see also researchers, as mediators
consumption studies, bringing technoscience studies to bear on, 109
contingency, of pharmaceuticals, 99
continuing medical education (CME), 150
conferences, satellite symposia, 106, 110, 140
on female sexual dysfunction (FSD), 111–12
continuing medical education (CME) (cont’d)
organization of as technique of commodification, 112
as technology of knowledge distribution, 112
credits, 108
commodification of, 110
ethics of, 110
Indian industry of, 225, 228
Controller General of Patents and Designs, 250
coordination campaigns, 135 see also channel marketing
copies
market for, 243
manufacture, distribution, and sale of, 264
Corcoran, A.C., 62
corporate integrity agreements, 160
corporate mode of science, 161
corporate power, 133, 135, 142–6
cultural theory of, 135
corporate production of knowledge, journal articles, 158–9
corporate solidarity, 248
Correa, Andrés, 193
Correa, Marilena, 11, 236
cortisone, 3, 187–8
cosmologies, Umyang and Ohaeng, 171
Council of Scientific and Industrial Research (CSIR), 249
counter-emplotment, 43 see also Martinez-Hemaez, A.
counter-science, 217
COZAAR (angiotensin receptor blocker), 100
credibility, FDA approval as certificate of, 96
cultural obstacles, 135 see also channel marketing
cultural text, pharmaceutical as, 5–6
Current Medical Directions (public relations firm), 151
cutting and pasting, as metaphor for pharmaceutical marketing practices, 42

Dana, Jason and Loewenstein, George, 111
data
integrity of, 218
management, 226–7
data-capture software vendors, 209 see also clinical development service providers
database construction, 36
De Cicco-Nardone, F., 152 see also authors; PC(2)
de Haen, Paul, 56
de Kruif, Paul, 58
de-medicalization, 20
DeBakery, Michael, 63
dependent normality, 44, 100 see also Dumit, Joseph
depharmaceuticalization, 20, 25, 29
depression, 28, 33–5, 41, 70–73, 75, 78, 80–81, 143
expansion of, 154
Depression Kit (Lilly), 34
deregulation, patients as means of, 26
Derrida, Jacques, 1, 88, 95, 99, 101 see also pharmakon
detailers, 9, 59, 124, 130 see also pharmaceutical sales representatives; drug reps
Diagnostic and Statistical Manual (DSM) controversy around premenstrual category in, 76, 79
3rd Edition (DSM-III), as representation of attempts to align psychiatry with medicine, 79
3rd Edition, Revised (DSM-III-R), 76
4th Edition (DSM-IV), 77, 116, 137
4th Edition, Depressive Disorder Not Otherwise Specified category, 81 see also premenstrual dysphoric disorder (PMDD)
working groups, 78–9
diagnostic bracket creep, (expansion of diagnostic definitions), 83, 109 see also Kramer, Peter
diet and cosmetic industries, 170
diet program using Korean medicine (KM), 170 see also Korean medicine (KM), scientization and industrialization of
dioscorea roots, 185 see also barbasco yam; cabeza de negro
diosgenin (steroid precursor), 185, 189 see also dioscorea roots
direct-to-consumer advertising (DTC), 9, 18, 22, 25–6, 33–4, 38–41, 43, 45, 83, 95, 112–13, 200
campaign for Sarafem, 78
campaigns, 142
exchange networks, between science and media, 200
and marketing, 112
and medical representation of mental illness, 80–81, 84
presented as educational campaigns, 75
prohibition in Europe, 75
role in mental health care debates, 74
direct-to-physician (DTP) initiatives, 140
disease mongering, 6, 18, 21–3, 25, 50, 138, 154
disease state prioritization, 137–8 see also
Moynihan, Ray
distribution channel, 133, 141, 145
members, 134 see also channel marketing
Diuril (chlorothiazide), 50–59, 62
campaign for, 60
competitor products, 62 see also Esidrix
(hydrochlorothiazide); Naturetin
(bendroflumethiazide); NaClex
(bentiazide)
as contender for Pill of the Year, 58
establishment as an antihypertensive agent, 57
Hygroton (chlorathalidone)
Diuril Heart, Kidney, 60
Diuril Man, 59–60, 62
News Report, 58
promotional imagery of, 60
Research Paper, 57
role in changing hypertension, 65
Djerassi, Carl, 188, 193
Doha Declaration, 245
domestication, of pharmaceutical consumption, 25
Dominguez, Eduardo, 193
Donna (Zyprexa patient profile), 138–40
see also patient profile; Zyprexa
Dow Jones Sustainability Index (DJSI), 252
Dr. Simi, 262–5
Drug Controller General of India (DCGI), 225, 228, 233 see also India, regulatory agents
drug donation programs, as part of global pricing strategy, 94, 258 see also Ecks, Stefan
Drug Enforcement Administration, 128
drug experience, 8
drug markets, growth of, 21
drug prices, 250
and leakages associated with lower prices, 257
drug reps see pharmaceutical sales representatives
drugs, creation of markets for new, 107, 109
see also attention deficit disorder (ADD); Ritalin; premenstrual dysphoric disorder (PMDD); Sarafem; social anxiety disorder; Paxil
Drugs for Life, 33
DSM see Diagnostic and Statistical Manual (DSM)
DTC Times (industry publication), 45 see also
Realto, Vern
Dumit, Joseph, 6, 18, 100
Durkheim, Émile, 145
Duster, Troy, 95
Eastern Europe, for clinical trials sites, 212
Echeverría, Luis, 189–91, 193, 265
Ecks, Stefan, 8, 10, 94, 236
economic value of pharmaceuticals, 180
education
in advertising, 42, 101, 112–13
awareness through, 36–7
as patient cultivation, 37
and training institutes for clinical research, 225
Eli Lilly (pharmaceutical company) 7, 70, 72,
74, 78, 84, 137, 140
campaign for Zyprexa, 122, 135
DTC campaign for Sarafem, 78, 80–82
Strategic Intent (1997), 138 see also primary care providers (PCPs); commoditization, as enemy of marketing
Ellison, George, 96
Elsevier (publisher), 162
emerging economies, as new markets for drugs, 23
Employee State Insurance Scheme (ESIS), 254
endocrinological drugs, 9
enganchar (hooking laborers), 188 see also barbasqueros; Mexico, labor issues
enhancements, medicines as, 27
entrepreneurial agent, Association of Black Cardiologists as, 92
equivalent medication, 214 see also ethics, of human subjects research
erectile dysfunction, 22, 107 see also Viagra
EROS, The, 116
Esidrix (hydrochlorothiazide), 62 see also Ciba; Diuril, competitor products
ethical calculus, and therapeutic access in India, 230
ethical figuration of experimental subjects, 231 see also informed consent
ethical guidelines
in India, 228
routine violations of, 219
ethical marketing, 59
ethical principle of autonomy, 180, 197, 204
informed consent
ethical response to consumer demand, separate branding of fluoxetine hydrochloride as, 71
ethical review boards, 214, 218
ethical standards in global clinical research, 212, 227
ethical variability, 210, 217, 227, 231
ethics
of conference presentation on off-label uses of and not-yet-approved drugs, 112
of continuing medical education (CME), 110–111
debate in terms of imperialism vs. relativism, 213 see also AZT Trial
as good clinical practice, 228 see also good clinical practice (GCP)
harmonization of, 231
of human subjects research, 196, 214
idealization in medicine, 114–15
link with regulation, 214, 233 see also regulation, of human subjects research situated, 223, 231
ethics code, International Society of Medical Planning Professionals (ISMPP), 160–161
European Medicines Evaluation Agency (EMEA), 23, 209
everyday, integration of pharmaceutical into, 44
evidence, lateral forms of, 122 see also Eli Lilly, campaign for Zyprexa
Excerpta Medica (publication planning firm), 162
excessive daytime sleepiness (EDS), 42
exchange networks
linkages with commodification techniques and technoscientific development, 106 see also commodification techniques; technoscientific development
researchers relationships with different actors as, 115
between science and media, 113
exchange relations, theories of, 116 see also King, Nicholas
Exclusive Marketing Rights (EMR), 249
expectations, role of in processes of technological change, 28
expected failure, paradigm of, 218 see also clinical trials
expert patient, 26
extrapyramidal symptoms (EPS), 139 see also primary care providers (PCPs), areas of concern
facts, conversion of patient stories into, 43 see also Martinez-Hemaez, A.
factual persuasion, 34
Far Manguinhos laboratory of the Oswald Cruz Foundation (Rio de Janeiro), 238–9, 241, 243–4
Farmacias de Dios, 262
Farmacias del Ahorro, 262
Farmacias Similares, 261–6 see also Mexico, pharmacies
fast-tracking approval for drugs, 23, 219 see also regulatory agencies, review times for drugs
Fazal, Anwar, 7
Federal Trade Commission (FTC), 59
Federal University of Rio de Janeiro, 242–3
female sexual dysfunction (FSD), 6, 22, 50, 106–7, 116, 154
classification schema for subtypes, 109
ethics of off-label drug recommendations for, 112
product development for treatment of, 108
research, 113–14 see also Tiener, Leonore
financial relationships
disclosures of, 116
effects of disclosure on bias, 111
influence on prescribing practices, 111
Fisher, Jill, 8, 92
Fishman, Jennifer, 6, 50, 154
fluoxetine hydrochloride, 70
clinical trials for use in PMDD, 80
generic, 72–3, 77, 82
approval as certification of credibility, 96
approval process, 218
approved technology for female sexual dysfunction (FSD), 116 see also EROS, The Centre for Drug Evaluation, 213
guidance on DTC advertising, 73
hearing on BiDil’s approval, 92
new drug application (NDA), 54, 219
original approval for schizophrenia, 122
Food, Drugs and Cosmetics Act, 6
Fortune magazine, 185–6
Fox, Nick and Ward, Katie, 25
Fox, Renée, 3
Frankenberg, Ronald, 38
Freis, Edward, 57, 62–3 see also Washington, D.C. Veterans’ Association Hospital
Freud, Sigmund, case studies, 140
friendship
false, 130–131
as a marketing strategy by drug reps, 123–7
Fugh-Berman, Adriane, 9, 122
Fujimura, Joan, 91
Fullwiley, Duana, 93
Fundación Best, 262
future patients, 38
Gabe, Jonathan, 18
Galen, materia medica, pharmacopoeia, 2, 7
Ganciclovir (HIV/AIDS drug), 239
Garcea, N., 152 see also authors; PC(2)
Gastrointestinal Stromal Tumours (GIST), 248
gatekeepers, 135 see also channel marketing
GCC Review (Novartis publication), 253 see also global corporate citizenship (GCC)
Geigy (pharmaceutical company), 63
generic pharmaceutical markets, 8
genérico intercambiable (GI), 263, 266
and the similar, 263 see also generics
genéricos de marca, 263
generics (drugs), 7, 236, 238, 261–2
erosion, Sarafem as tactic to combat, 78
local production of in Brazil, 239, 241, 245
market for in Mexico, 261
markets, 224
politics of, 265
and production in India, 251
and synthesis routes, 242–3
genetic and genomic knowledge, 27
-genetic testing, and racial politics, 28
Genepian, Van, 41
Genomic Glossaries: Evolving Terminology for Emerging Technologies (webpage of Cambridge Healthtech Institute), 116 see also robust pipelines
Gereffi, Gary, 189
Getting to Yes (book), 142
going to yes, as a strategic proposition, 142–4
guest management of research and publication, 150–151, 158

guestwriting, 122, 141, 155, 157–9, 161
gift
focus on in critiques of BiDil, 92
power of the, 92–3
as tool for developing loyalty, 124

Gift, The (book), 248 see also Mauss, Marcel
Gilead (pharmaceutical company), 238
GlaxoSmithKline (pharmaceutical company), 240
Gleevec, 8 see also Glivec
Glioblastoma Multiforme, 256
Glivec (imatinib mesylate), 236, 247–58
global pricing strategy, 258
Indian market for, 256
and production of generics, 255, 257
retail price of, 256
Glivec International Patient Assistance Program (GIPAP), 253–7
global commodities, pharmaceuticals as, 5, 7
global corporate citizenship (GCC), 253, 258
see also Novartis
global scientific regime, 166
globalization, 22
of manufacturing, 23
of western regulatory system, 23
-goal conflict, 135–6, 141 see also channel marketing
Gold, Judith, 84 see also American Psychiatric Association (APA), PMDD Work Group
good clinical practice (GCP), 227–9, 231, 233
Good, Maryjo Delvecchio, 43
Good Publication Practice, 155 see also publication planning and planners
good to think with, objects as, 65, 96 see also Levi-Strauss, Claude
Gouveia, Roberto, 237
governance, changing forms of, 22

grammar
of BiDil website, 94–5
of experience, 33–4
of illness, 33–5
of racial indication, 93
as representation of difference between PMDD and PMS, 82
of risk, 33–4
of subliminal marketing experiences, 44
of treatment, 33–4
Greene, Jeremy, 6, 50
Greenslit, Nathan, 7, 50, 96
grey literature, 34
growth market, of bipolar disease, 122
Grupo por un País Mejor, 262
guaiac bark (anti-syphilitic), 7 see also New World, objects brought from
Gulhati, Chandra, 228, 230
Haak, Hildebrak, 4
Hamilton, Jean, 76 see also Premenstrual Advisory Committee
Haraway, Donna, 98 see also material-semiotic
Hardon, Anita, 4–5
harm and harm detection, 8, 216, 218
Hayden, Cori, 7–8
Headrick, Daniel, 4
health activists, 247, 258
health consumer groups, 26
health feminism, 6
health futures, colonization of, 27
health information, moral grammar of, 37
health information organizations, 128
health literacy, 37
Healthcare Financial Management Association, 223
Healy, David, 80, 109, 138, 151, 154
heart disease, as central to health concerns, 55
heart failure
as a diagnostic category, 88–9
limitations on potential markets for therapeutics, 90
as patient’s illness, 89 see also Aronowitz, Robert
stages of, 89
Heath, Fred, 56
hegemony, over medical knowledge, 9, 27
Helsinki Declaration, 213–14, 219
Herbal Medicine Dispute in Korean Medicine, 167 see also Korean medicine (KM)
Hetero (pharmaceutical company), 252
hierarchy of knowledge production, 167–8 see also Korean medicine (KM); knowledge, global hierarchy of production hierarchy, of social life reshuffled, 181
high blood pressure see hypertension
high-prescribers, 128 see also prescription
HIV/AIDS drugs, 237–8, 243, 251
policy of universal access to in Brazil, 238–40, 244
HIV/AIDs, in Brazil, 236–7
Holmes, Oliver Wendell, 2
hormonal model of the human body, 183
hormones, 181, 183, 186
production of, 183, 191
synthetic alternatives to, 188
Hull, Richard, 59
hybrid categories, production of by modern science, 98 see also Latour, Bruno
hybrid gift-commodities, 248 see also Mauss, Marcel
hybrid science, 122
hybridization, of medical practices, 165, 169, 175 see also Korean medicine (KM)
HydroDiuril (hydrochlorothiazide), 62
Hygroton (chlorothalidone), 63 see also Geigy; Diuril, competitor products
hypertension, 6, 50–52, 55, 63
altering the definition of, 61
asymptomatic, 6, 64
as a category of treatable risk, 61
as a cause of heart failure, 89
as doctor’s disease, 89 see also Aronowitz, Robert
as inaccurate indication for BiDil, 88
promotion as the silent epidemic, 64
researchers, 61
treatment, 57, 64
imatinib mesylate see Glivec
IMS Consulting, 129
intermediaries, 133, 144 see also channel marketing; distribution channel, members
International Classification of Diseases (ICD) (World Health Organization), 79, 115
International Committee of Medical Journal Editors (ICMJE), 157
criteria for authorship, 158
International Conference on Harmonization (ICH), 8, 23, 214, 224
Guideline for Good Clinical Practice, 213
International Monetary Fund (IMF), bailout program, 167
International Organization of Consumers Unions, 7
International Publication Planning Association, The (TIPPA), 152–3, 155–6
International Society of Medical Planning Professionals (ISMPP), 152–3, 155–6
code of ethics, 160
standard of good publication practice, 160
interpellation, 35, 39, 73, 81, 83 see also Althusser, Louis
Intrinsa (testosterone patch), 116 see also testosterone-replacement patch for women
investigative site management organizations, 209 see also clinical development service providers
investigators, recruited, 218
Ismelin (guanethidine), 64 see also Ciba; catecholamine blockers
isosorbide dinitrate and hydralazine (I/H) see BiDil
Janssen (pharmaceutical company), 137
Joint National Committee (JNC) Report on Detection, Evaluation, and Treatment of High Blood Pressure, 64
Jones, David, 88
Jones, Kathryn, 25
journal advertisements
influence on prescriber decision making, 59
pages per medical journal, 60
spending on, 60
Journal of the American Medical Association (JAMA), 57, 60, 116, 153
Journal of Women’s Health, 80
journal publications, 57
Kahn, Jonathan, 92, 95–6, 98
Kaletra (HIV/AIDS drug), 238, 244, 246
generic equivalent of, 244
Katz, Elihu, 3
Kearney, A.T., 224, 226
Kefauver, Estes, 6
Kennedy, Edward, 205
key communication messages, 151
key opinion leader (KOL), 143, 156, 158
Kim (Director of Purimed L.A. Branch), 174
Kim, Jongyoung, 5, 122
King, Nicholas, 116
knowledge
affective investment of makers, 166
creation through mediation, 159 see also publication planning and planners, as creative mediation
and development economy, 245 see also Romer, Paul
global hierarchy of production, 166 see also Korean medicine (KM)
pharmaceuticals as sites of production, 5, 8
production and circulation, 122
and science combined with politics, 186
of usefulness of pharmaceuticals, 180
KOL authors, 158 see also key opinion leader (KOL)
Kolkata, 251
Kopytoff, Igor, 4
Korea Sport Science Institute, 169
Korea University, 173
Korean medicine (KM), 5, 122, 165
expansion of boundary, 165
paradox, 166, 173
and scientific verification of treatments, 165
scientization and industrialization of, 165, 167–9, 171, 173, 175–6
as tool of class distinction, 171
as transcultural global assemblage, 174–6
traditional, 165
Koreanness, of Purimed products, 174
Kramer, Peter, 74, 83, 109
Krieger, Nancy, 98
Kroll-Smith, Steve, 24, 63
Kuryloski, Eugene, 63
Kyung Hee University, College of Oriental Medicine, 165–6, 169, 171
as capital of Korean medicine (KM), 174 see also Korean medicine (KM)
Laboratorios Best, 261–4
Laboratorios Hormona, S.A., 185
Lajouwe, Jane, 246
Lakshmikumaran, Mr., 252
Lambda (contract research organization), 225
Lamisil (antifungal) 37–8
Lancet (journal), 216
Langford, Jean, 171
Lasker Award, 55, 63
Lasker Foundation, 63
Lasker, Mary, 63
late luteal phase dysphoric disorder, 76 see also premenstrual dysphoric disorder (PMDD)
Latour, Bruno, 98, 116, 182
Lee (CEO of Purimed), 169–70
Lee, Je-Ma, 170 see also Korean medicine (KM)
Lehmann, Federico, 185–6
Leiter, Valerie, 22
Lescohier, Alexander W., 184 see also Parke, Davis & Company
Levi-Strauss, Claude, 50, 65, 96
Lewis, Sinclair, 58
Life (magazine), 59
lifestyle drugs, 89, 108
Lifetime Living (magazine), 58
Lipitor (atorvastatin), 90, 100
Listening to Prozac (book), 74 see also Kramer, Peter
Lopinavir (HIV/AIDS drug), 241
low-prescribers, 130
low sexual desire, as a primary sexual complaint, 108
Luther, Martin, 2
Lycii Fuctus (herbal ingredient in Korean medicine), 174
Lydia E. Pinkham Medicine Company, 9
lyophilization methodology, 239–40
made-to-order-journals, 162
Madras High Court, 250
managed care providers, 73, 115
manuscripts, industry-sponsored, 156–8, 161
Marker, Russell, 183–6, 192
market capitalism, 166
market expansion, patients as means of, 26
Market Leader (publication), 134
marketing, 35–6, 38
channel see channel marketing
classification of doctors for, 123
doctor research, 122
medical education and communication company (MECC), 152
medical exceptionism, golden age of, 114–15
medical journals, 156–7, 161
editors of, 157
publication of articles, 122
medical science liaisons, 155
medical writers, 151, 154–5
as research, 22
research, 122
strategies, 34, 151
techniques, 199–200
techniques used by pharmaceutical sales representatives, 122–3
Massachusetts Institute of Technology (MIT), Centre for the Study of Diversity in Science, Technology and Medicine, 87
materi medica, 2
material-semiotic, 98
BiDil as, 87–8, 97–8 see also Haraway, Donna
Mattingly, Cherly, 43
Mauritius, 245
Mauss, Marcel, 92, 248
MaxStation, 254
Mazur, Jan, 215–16 see also Pharmexel
McKinnell, Hank, 155
McKinsey Report, 225
me-too drugs, 210, 215
Medco, 91
Médecins Sans Frontières (MSF), 251, 254
media, and commodification of female sexual dysfunction (FSD), 112
mediation, 23, 25
pharmaceutical as agent, 5
medical education and communication company (MECC), 152
medical exceptionalism, golden age of, 114–15
see also Tomes, Nancy
medical identification, 38
medical journals, 156–7, 161
editors of, 157
publication of articles, 122
Medical Marketing Service, 128
Medical Research Council (MRC) streptomycin trials, 8
medical science liaisons, 155
medical writers, 151, 157–9, 161
and corporate production of knowledge, 159
medicalization, 5, 6, 25, 38
calls to rethink, 20
of a condition, 108
and disease mongering, 22
of gendered inequity, 6
as power conflicts, 38
role of pharmaceutical industry in, 20
of science news, 112–13 see also Bauer,
Martin
of society, 112–13
strategic, 145
medicamentos genéricos, 263
Medicare, 202
medications, as incentives to participate in
clinical research trials, 198, 200–201
medicinal plants, global search for, 181
Medicine and Health Care Products Regulatory
Agency (MHRA), 22–3
medicine, as element of mass culture, 112–13
see also media, and commodification of
female sexual dysfunction (FSD)
medicine, history of, 183
Menzel, Herbert, 3
Merck (pharmaceutical company), 50, 60, 62–4,
91, 128, 151, 156, 162, 216, 238
research facilities, 56
Merck, Sharpe & Dohme (MSD), 51, 53–5,
57–8, 61–3, 65
methods patent, BiDil as, 90
Mexican Chemical Society, 186
Mexico
labor issues, 185–7, 189–91
market for generic medicines in, 261
pharmacies, 236
reconfiguration of health politics in, 262
Ministry of Water Resources (SAG), 190
miracle drugs, production of by Merck
Company’s research laboratories, 53
Miranontes, Luis, 188
moral economy, 10 see also Thompson, E.P.
moral-cultural alignment, 135 see also channel
marketing
mortality burden, shift in, 63
Mouffe, Chantal, 88
Moynihan, Ray, 21
MSD Sales Dispatch (corporate publication), 60
multiple sclerosis, 25
NaClex (benzthiazide), 63 see also Robins;
Diuril, competitor products
narcolepsy, 26
National Association for Advancement of
Coloured People (NAACP), 92, 98–9
New England Area Conference of, 88
National Association for the Mentally Ill
(NAMI), 135
funding of by Eli Lilly, 137
National Autonomous University of Mexico
(UNAM), 186
National Coalition for Women’s Mental Health,
76
National Health Service, 25
National Heart Lung and Blood Institute, 89
National High Blood Pressure Education
Program (NHBPEP), 63–4
National Institute for Forestry Research (INIF),
189
National Institute of Cardiology (Warsaw), 209
National Institute of Mental Health (NIHM),
79–80, 136
National Institutes of Health (NIH), 63, 213
Antihypertensive and Lipid Lowering
Therapy to Reduce Heart Attacks Trial
(ALLHAT), 64
National Minority Health Month Foundation,
92
National Movement Against Corruption, 261
National Pharmaceutical Council, 59
National Sample Survey in India, 254
National Women’s Health Network (NWHN),
75
Naturetin (bendroflumethiazide), 62 see also
Squibb; Diuril, competitor products
Nelfinavir (HIV/AIDS drug), 246
Nelkin, Dorothy and Laurence Tancredi, 34–5
Nelson, Alondra, 93
neoliberal ideology, 23
neoplastic drugs, 8
New Chemical Entities (NCEs), 249–50
new gold, pharmaceuticals as, 216
new media, 25
New World, objects brought from, 7
New York Academy of Sciences (NYAS)
conference and proceedings, 56–7
Nguyen, Vinh-Kim, 248
niche model drugs, 90 see also drugs for life
Nichter, Mark, 4
Nissen, Steven, 92
NitroMed (pharmaceutical company), 87, 91–2,
94–5, 98, 101
NitroMed Cares drug donation program, 94
non-compliance, 37
on-medical use of drugs, 26
non-official diagnosis, PMDD as first FDA-
approved indication for, 78 see also
premenstrual dysphoric disorder
(PMDD); Food and Drug Administration
(FDA)
normative marketing channel management, 135
North American Free Trade Agreement
(NAFTA), 266
Norvasc (calcium antagonist), 153
Novak, Renata, 209
Novartis (pharmaceutical company), 236, 247, 249–50, 253, 255–7
and Caring and Curing, 253
and court case against Indian government, 248, 251–2, 255, 259
as Dow Jones Super Sector Leader, 252
global corporate citizenship (GCC) programs, 253
Indian unit, 253
and The Max Foundation (TMF) Sandoz division, 255
Nundy, Samiran, 228, 230

objective self-fashioning, 39
obligatory passage point, 116 see also Latour, Bruno
off-label uses of drugs, 76, 107, 112
Office of the Inspector General, U.S., 110, 214
Oldani, Michael, 124
Ong, Aiwa, 175
Oprah Winfrey Show, 113
organized medicine and organized pharmaceutical industry, alliances of, 10
Organon (pharmaceutical company), 152, 183
original position, 229 see also Rawls, John
Other and Unspecified Special Symptoms or Syndromes, Not Elsewhere Classified, 76
Other Disorders of the Female Genital Tract, 79 see also International Classification on Disease (ICD) (World Health Organization)
ouch test, 38
Oudshoorn, Nelly, 181, 183, 192
outsourcing, of drug development, 23
over-the-counter (OTC) medicines, 25
advertising, 112–13
overactive bladder, 203
Oxfam, 250

package insert, 227
Page, Irvine, 62
palm acupuncture, 167 see also Korean medicine (KM)
Paracelsus, 2
iatrochemistry of, 7
Park, Chan, and Prabha, Achala, 252
Parke, Davis & Company (pharmaceutical company), 184
Parsons, Talcott, 3
Parthenon Publishing, 152–3
pass-through persuasion, 42
Pasteur, Louis, 116 see also Latour, Bruno
pastoral care, 230
patent medicines, 3
advertising of, 22
patents, 236–7, 243–5, 250, 256–7
exclusions of, 238, 240
laws in India concerning, 244, 247, 249
patentable objects, 237, 244, 247
regime of, 10
value of, 138
violations in Mexico, 236
patient advocacy groups, 25, 135, 217
overlap with consumer advocacy, 73
patient rights movements, 115
patient social movements, 43
patient data mining, 209
patient-in-potential, 40
patient profile, 140
patient self-selection, 38–9
patients, reconceptualization of, 212
Paxil (antidepressant), 109 see also social anxiety disorder
PC(2) (manuscript), 152 see also Wyeth; publication planning and planners; Premarin/trimegestone hormone therapies
peasant movements, in Mexico, 183 see also campesinos; Mexican
Pecheux, Michel, 42
penicillin, 4, 54
personalization, 35, 40
personalized medicine, BioDill as a step toward, 93
Persson, Asha, 95, 97
persuasion, processes of, 36
Peruvian bark (antipryetic), 7 see also New World, objects brought from
Petryna, Adriana, 8, 224, 227, 247
Pfizer (pharmaceutical company), 83, 113, 137, 151, 153, 155, 214
pharmaceutical anthropology, 4
pharmaceutical citizenship, 248
pharmaceutical emissary, Association of Black Cardiologists as, 92
pharmaceutical futures, 27
pharmaceutical knowledge, circulation of, 122
pharmaceutical manufacturer-physician relations, guidelines for managing, 110 see also Office of the Inspector General
Pharmaceutical Manufacturers Association (PMA), 16, 57 see also Pharmaceuticals Research and Manufacturers of America (PhRMA)
pharmaceutical regime, 20, 21
Pharmaceutical Representative (industry publication), 129
Pharmaceutical Research and Manufacturers of America (PhRMA), 10, 160, 253
pharmaceutical sales representatives, 123–4, 128–30
pharmaceutical studies, key themes, 4
pharmaceutical witnessing, 33, 42
pharmacogenomics of anti-depressant medications, 28
BiDil in framework of, 93 see also Fullwiley, Duana
and pharmacogenetics, 27
pharmacopoeia, 53
pharmakon, 1, 5, 101 see also Derrida, Jacques
BiDil as, 87–8, 95–6
Physician Masterfile, 128 see also American Medical Association (AMA)
physician profiling, 122
marketing techniques, used by pharmaceutical sales representatives, 122–3
Picon, Paulo, 216
Piramal, Nicholas, 225
placebos, 212–14, 219
and the efficacy of clinical trials, 8
placebo effect, 4
Poland, clinical trials in, 209, 215–16
political economy, 4, 166
Pollock, Anne, 6, 50
postcolonial and transnational studies of Asian Medicines, 166
postwar therapeutic innovation, 52
potential drug users, creation and configuration of market of, 109
potential human subjects, 201–2
Poulenc laboratory (France), 246
power, concealment of, 144 see also channel marketing
power relations, within globalized Korean medicine (KM), 175–6 see also Korean medicine (KM), as transcultural global assemblage
Premarin/trimegestone hormone therapies, 152
Premenstrual Advisory Committee, 76
premenstrual dysphoric disorder (PMDD), 7, 50, 70–71, 73, 75–6, 78–9, 109
diagnostic code for, 76
gynecological authority over, 79, 81
as a new illness category, 78
opposition to based on scientific framework, 76
PMDD work group, 76 see also Sarafem
premenstrual syndrome (PMS)
ownership of, 75
premenstrual tension syndromes, 79
spectrum of, 82
PreMysyn ad campaign, 81
preparing the market, 37
prescribing behavior, changing through detailing, 130
Prescribing Data Restriction Program (American Medical Association), 129
prescription
maximization, 36
tracking (script tracking), 128
prescription-only medicines, reclassification of, 25
prevention, language of, 143
preventive treatment, shift in logic of, 63
price, power and meaning of, 93 see also gift, power of the
Prilosec (omeprazole), 38–9
primary care providers (PCPs), 138
areas of concern, 139
transferring prescription responsibilities to, 140
pro-anorexia websites, 25
process patents, 240
processualism, method of, 34 see also Turner, Victor
Procter and Gamble Pharmaceuticals, 108
product advocacy, 44
product cycle, 36
product loyalty spheres, 139
product profile, 151
productivity crisis, 23
progressive account of pharmaceutical expansion, 21
Proquivemex, 190
Prozac (fluoxetine), 7, 25, 50, 70, 72–3, 76–7, 82
loss of prescription volume, 77
patent expiration, 78 see also blockbuster
drugs
psychopharmaceuticals, 6, 50, 70, 133
demarcation of essential from inessential, 83
and medical representation of mental illness, 80–81
public goods, drugs as, 244
public health, 208, 237–9, 244–5
changing role of regulators, 23
interests of, 22
justification for response, 37
pharmaceuticalization of, 217 see also Biehl, Joao
Public-Private Partnerships (PPP), 256
Publication Planning 101/10, 153
publication planning and planners, 9, 122,
151–3, 156–7, 159, 161
campaigns, 154, 156
conferences, 157–8
see also knowledge, creation through
mediation
distinct from public relations, 154–5
firms, 156
guidelines, 158
multiplication of contributors, 160
relations with publishers, 156
teams, 154
publishing, transactional view of, 157
Pure Food and Drugs Act, 3, 6
Purimed (Korean Medicines company), 165–6, 168–9, 172–3, 175–6
quality of care, 208
Quantum Learning (marketing company), 129
Quinine, 4
Quintiles (contract research organization), 227
Race, Pharmaceuticals and Medical Technology
(conference), 87 see also Massachusetts
Institute of Technology
race, reality of, 98
mediation of, 99
reduction of biological to genetic, 98, 102
racial indication, 50, 87–8, 90
characterized as palatable, 96
grammar of, 93
as harm to cause of antiracism, 95
as symbolic mistake, 96 see also symbolic
mistakes; Greenslit, Nathan
unpalatability of, 95, 99
racial reification, risk of, 88
Rahway, New Jersey (Merck headquarters), 56
Rajan, Kaushik Sunder, 8
Ramirez, Pedro, 193
Ranbaxy (pharmaceutical company), 224–5, 250, 252
randomized controlled trial (RCT), 159, 175, 180
as biomedical knowledge-making, 8
rational drug design, 64
Rawls, John, 229
Razo, Roberto Pena, 193
Reader’s Digest, 58–9
reader’s domination, 43
ready-to-consent, 195–6, 199, 205
ready-to-recruit, 195–6
Realto, Vern, 38–9
reassurance symbols, 62
Reeves, Dan, 39
Regier, Darrel, 78 see also American
Psychological Association (APA),
Division of Research
regimes of pharmaceutical standardization, 236
registers of danger and remedy, associated with
BiDil, 95
regulation of pharmaceutical markets, 5, 10
infrastructure, 227
process, 36
regulatory agencies
funding of, 23
review times for drugs, 23, 28
role of in promoting innovation, 22
rejection rates, of medical journals, 155
renal physiology, utility of for pharmaceutical
development, 54
rescue studies, 215–16
research activity, as marketing, 114
research and development (R&D)
and clinical trial subject recruitment, 211
copying as, 241, 243, 245
globalization of, 180
landscape of, 180
and market risk, 223
as pharmaceutical nationalism in Mexico, 265
public ignorance about, 200
as a resource, 150
uncommon trajectories of, 183
researchers
as integral to bringing new drugs to market, 107
as media celebrities, 112–13
as mediators, 109–14
resemblances to detailers, 112 see also key
opinion leader (KOL), pharmaceutical
sales representatives
retroactive status change in health and illness, 35
reverse engineering, 224, 240, 245
risk
  health as reduction of, 33
  personalizing, 36, 38–40
risk-factor charts, 40
Ritalin (methylphenidate), 26, 109 see also attention deficit disorder (ADD)
Ritonavir (HIV/AIDS drug), 241
Robert Wood Johnson Medical School, 108
Roberts, Dorothy, 88
Robins (pharmaceutical company), 63
robust pipelines, 115–16 see also Genomic Glossaries: Evolving Terminology for Emerging Technologies (webpage of Cambridge Healthtech Institute)
Roche (pharmaceutical company), 193, 239
rofecoxib see Vioxx
Romer, Paul, 245
Rose, Nikolas, 247, 257
Rosenberg, Charles, 3, 5
Rosenkranz, George, 186
Rubinow, David, 79 see also National Institute of Mental Health (NIMH)

safeguarding human subjects, regulation for, 196–7, 205, 210
Salazar, Raúl Molina, 263
sample-grabbers, 129 see also classification of doctors, as a marketing strategy
samples of drugs, 129
  influence on prescribing choices, 129
  tracking program, 129
  as unacknowledged gifts, 129 see also gifting, as tool for developing loyalty
sampling device, pharmaceutical as, 4
Sandoz (Novartis), 37
São Paulo University, 243
Sapru, Y.K., 254
Sarafem (fluoxetine), 7, 50, 70–74, 79, 82–3 campaign, 75
  launch of as economic move, 77
  marketing of as education about PMDD, 80
  media coverage of launch, 78
as medical/corporate instrusion, 71
as recognition of uniquely female medical condition, 71
symbolic life of, 83
as tactic to combat generic erosion, 78 see also premenstrual dysphoric disorder (PMDD), as a new illness category
Sasang constitution medicine, 167, 171 see also Korean medicine (KM)
Satcher, David, 213
satellite symposiums, 127, 140 see also continuing medical education (CME), conferences, satellite symposia
Saturday Evening Post, 58–9
Schedule Y, 228, 233 see also ethical guidelines, in India
Schering-Plough (pharmaceutical company), 262
Schering (pharmaceutical company), 183
schizophrenia, 136–8, 141 see also Zyprexa, evolution of
Schott, George, 54–5, 57–8
Schroeder, Henry, 62
Science and Technology Studies (STS), 2, 19, 29, 30, 161, 166
science, conversion into marketing, 34
scientific standards, importance of to publication planning, 155
scientism, 167, 171
screening programs, 36
script tracking, 128–9 see also prescription
Seal of Acceptance program (American Medical Association), 53
Searle (pharmaceutical company), 188
Secretary of the Environment (SEMARNAP), 190
Seguro Popular, 262
Seguro Social, 261, 263, 265
selective serotonin reuptake inhibitors (SSRIs), 139, 143
  and rise of depression disorders, 109
self-diagnosis, 42
  motivation to, 36, 40
self-help, 40
  commercialization of, 113
self-identified black patients, 87–8, 93
  heart failure in, 94
  indication for heart failure in, 87–8
selling sickness, 6, 18, 21, 154 see also
  Moynihan, Ray
sertraline (Zoloft), 151
sex endocrinology, 183
sexual dysfunction disorders, in DSM-IV, 115
sexuopharmaceuticals, 107, 109 see also Viagra
  as fetishized commodities, 113
  as lifestyle drugs, 108
Shahani, Ranjit, 253 see also Novartis, Indian unit
share of voice (SOV) leadership, 140–141 see also channel marketing
Sharpe & Dohme (pharmaceutical company), 53, 56
  renal program of, 54 see also Merck,
  Sharpe & Dohme (MSD)
shopping cart ads, for Sarafem, 75, 78
side effects, 24, 41, 45, 54, 62, 96–7, 144, 200, 201, 203, 214, 218
adverse events in clinical trials, 9, 216, 230–231
of antipsychotics, 136–7, 139
symbolic, 77–9
Silverman, Milton, 3
Simi revolution, and those who have the least, 262
SimiSeguro, 262
Similares, 261–2, 264–5
Sismondo, Sergio, 122
skin disease treatment, using Korean medicine, 171 see also diet and cosmetic industries; Korean medicine (KM), scientization and industrialization of
sleepiness, social construction of, 25
Smith, Austin, 57
Smith, Dorothy L., 39
Smith, Kline and French (pharmaceutical company), 59
Smith, Mickey, 3
Smith, Richard, 156
social anxiety disorder, 109 see also Paxil
social construction of illness, replacement of, 21 see also construction of disease, by corporations
social lives of medicines, 5, 71
sociology of expectations, 27
Somlo, Emeric, 185–6
Son (doctor of Korean medicine), 171 see also Korean medicine (KM); hybridization, of medical practices
Soto Laveaga, Gabriela, 5, 9, 180
Spiegelmann, Daniele, 152 see also Wyeth; authors; PC(2)
Spitzer, Robert, 79 see also Diagnostic and Statistical Manual (DSM), working groups
Squibb (pharmaceutical company), 62
Srîstek (contract research organization), 227
steroid hormones, 181, 191
global demand for, 185
history of, 183, 192
nationalization of industry, 190
production in Mexico, 186
search for substitutes, 183–4
stimulant coca leaves, 7
New World, objects brought from structural violence, 145–6, 228, 231–3
subject effect, 39 see also Althusser, Louis sulfanilamide scandal (1983), 59
Swazey, Judith, 3
symbolic incompatibility, 73
symbolic mistakes, 71, 83
prevention of through design of drugs by color, 72
racialized drugs as, 96 see also Greenslit, Nathan
symposia, 57 see also continuing medical education (CME)
syndrome differentiation and therapy determination, 170 see also Korean medicine (KM), traditional
synergistic power, 133, 142–3, 145–6 see also corporate power
Syntex (pharmaceutical company), 184–9, 192–3
as global supplier of synthetic hormones, 188
synthesis, 239–41
Tan, Michael, 4
Tarbell, Ida, 3
technological learning
by copying antiretrovirals, 237, 241, 242
by preparation of compulsory licenses, 245
technological procedures, junctions with consumers, 106
technology transfer, 240, 242–3, 245
technoscientific development, 106 see also exchange networks; commodification techniques
Temple, Robert, 213
testosterone-replacement patch for women, 108 see also female sexual dysfunction (FSD), product development for treatment of testosterone therapies, as off-label treatments for female sexual dysfunction (FSD), 112
The Max Foundation (TMF), 253–4, 257
The Therapeutic Revolution, 3
therapeutic emplotment, 43
therapeutic equivalence, 73
therapeutic misconception, 206
Thompson, E.P., 10 see also moral economy
Thomson Scientific Connexion (publication planning firm), 156
thought leaders see key opinion leader (KOL)
Tiefer, Leonore, 22, 116
Time magazine, 59
Times of India, 252
Tomes, Nancy, 114
Torres, González Victor, 262, 264–5, 261
Totelle (hormone replacement therapy), 112
thought leaders see key opinion leader (KOL)
Tiefer, Leonore, 22, 116
Time magazine, 59
Times of India, 252
Tomes, Nancy, 114
Torres, González Victor, 262, 264–5, 261
Totelle (hormone replacement therapy), 152
toxicity, of connection between drugs and race, 97
trademarks, 236
transcultural medicine, 174–5
transnationality, 175 see also Ong, Aihwa
treatment naïve populations, 180, 213–5, 226
see also clinical trials, participation and recruitment
treatment-saturated markets, 218, 226
Trimegestone 301 Study Group, 152 see also authors; PC(2)
TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights), 10, 236, 247, 249
tritherapies, distribution of in Brazil, 238–9
trivialization, language of and Sarafem advertisements, 75
Trovan (antibiotic), 214
truth-effect, 39
Turner, Victor, 34, 40–41, 44
Tuskegee experiment, 96, 219
Underwood, Paul, 98
Unit of Clinical Research of the University Hospital (Brazil), 210, 216
United States Public Health Service, 63
University of California at Los Angeles Female Sexual Medicine Center, 113
University of Chicago, 168 see also Bae (Professor of Korean medicine)
University of Medicine and Dentistry of New Jersey, 108
unmet needs
of consumers of healthcare, 134
creating an understanding of, 154
unrestricted educational grants
as key area of potential risk, 110 see also continuing medical education (CME)
Upjohn (pharmaceutical company), 188
urine, as source of pure hormones, 183
vaginal endometriosis study, 204
Valium (diazepam), 3
value generation, logics of, 224
van der Geest, Sjaak, 4–5
Vargas, Getulio, 240
Varmus, Harold, 213
Vasco da Gama, 7
Vasella, Daniel, 250, 255–6 see also Novartis
Vasodilator in Heart Failure Trials (V-HeFT), 90–91
retrospective analysis of blacks participants in, 91
role in hearing on BiDil’s approval, 92
Veatch, Robert, 197
Venkatesh, Viji, 254
Veterans Affairs (VA)
Trial, 63
US Department of, 90
Viagra (sildenafil), 25, 83, 113
as an off-label treatment for female sexual dysfunction (FSD), 112
and Pfizer, 115
as a treatment for erectile dysfunction, 107
Vimta Laboratories (contract research organization), 229
Vioxx (rofecoxib), 89, 156, 216
lawsuits about, 151
Vogel, Morris, 3
von Hohenheim, Phillippus Bombastus (Paracelsus), 2
Vukovic, Nancy, 4
Wall Street Journal, 94, 155
Washington, D.C. Veterans’ Association Hospital, 62
Washington Post, 78–9
Watson Pharmaceuticals, Inc., 108
weight of evidence, behind Diuril usage, 60, 62 see also Diuril
Wellquest (contract research organization), 225, 232
Wetherell, Miles, 3
Whyte, Susan Reynolds, 4–5
Wilkins, Robert, 57
Williams, Simon, 5–6, 18
women
health groups opposed to PMDD, 76, 78 see also Premenstrual Advisory Committee; American Psychiatric Association (APA), Committee on Women; National Coalition for Women’s Mental Health and the ownership of PMS, 84
representation of in psychopharmaceutical advertisements, 75
Women’s Health Initiative (WHI), 152
World Trade Organization (WTO), 224, 245, 252
Wright, Jean, 152 see also medical education and communication company (MECC)
Wyeth (pharmaceutical company), 152, 162
Ye Oriental Clinic, 166, 168–9, 175
Young, James Harvey, 3
Zocor (simvastatin), 39, 40
Zoloft (sertraline), 41
zones of crisis, 210
Zyprexa (olanzapine), 122, 135–8, 144
approval for short-term use in acute bipolar mania, 140
evolution of, 136
global rollout, 142
The Integrated Product Plan for 2001, 140 see also Eli Lilly